Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TSC-201-B0702 + TSC-204-C0702 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TSC-201-B0702 | TSC 201-B0702|TSC201-B0702 | Limited information is currently available on TSC-201-B0702, a putative T-cell receptor (TCR) therapy targeting MAGE-C2 presented on HLA-B*07:02 (Jun 2024). | ||
| TSC-204-C0702 | TSC204-C0702|TSC 204-C0702 | TSC-204-C0702 comprises autologous T-cells engineered to express a T-cell receptor (TCR) targeting the MAGE-A1 antigen presented on HLA-C*07:02, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing MAGE-A1 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05973487 | Phase I | TSC-200-A0201 + TSC-204-C0702 TSC-203-A0201 TSC-201-B0702 + TSC-204-A0201 TSC-200-A0201 TSC-204-A0101 + TSC-204-A0201 TSC-201-B0702 TSC-201-B0702 + TSC-204-C0702 TSC-204-A0101 TSC-204-A0101 + TSC-204-C0702 TSC-204-A0201 + TSC-204-C0702 TSC-200-A0201 + TSC-204-A0201 TSC-204-C0702 TSC-203-A0201 + TSC-204-C0702 TSC-204-A0201 TSC-203-A0201 + TSC-204-A0201 TSC-201-B0702 + TSC-204-A0101 TSC-201-B0702 + TSC-203-A0201 TSC-200-A0201 + TSC-204-A0101 TSC-200-A0201 + TSC-203-A0201 TSC-203-A0201 + TSC-204-A0101 TSC-200-A0201 + TSC-201-B0702 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |